BIOGENERATION III SERVICES

BioGeneration III Services is the management company for BioGeneration Ventures Fund III, a specific early-stage life sciences fund. The broader BioGeneration Ventures platform began investing in 2006 across multiple fund vintages, and Fund III held its first close in 2017 targeting Benelux and Western European life sciences opportunities.

It manages third-party capital on behalf of limited partners in BioGeneration Ventures Fund III. The entity functions as the fund's management company and advisor — it does not operate as a family office or proprietary investment vehicle, and its returns flow through carried interest rather than direct co-investment from a family balance sheet.

The fund targets seed and Series A rounds, with a focus on preclinical through early-clinical-stage therapeutics, medical devices, and enabling technologies. The firm's sourcing prioritizes academic-spinout science from Benelux institutions such as the Netherlands Cancer Institute and KU Leuven, where the intellectual property is still unpartnered and the valuations remain disconnected from commercial expectations.

Prior to Fund III, the BioGeneration Ventures platform backed Dezima Pharma, a cholesterol drug developer that Amgen acquired in 2015 for up to $1.55 billion in milestone- and earnout-structured consideration (per Amgen, 2015). That exit demonstrated the platform's model of building single-asset companies to an inflection point and then selling to a major biopharmaceutical acquirer.

The firm sources primarily from academic and research-hospital spinout ecosystems in the Benelux region, particularly in the Netherlands and Belgium. Its proximity to institutions like the Netherlands Cancer Institute and the life sciences cluster around Leiden and Amsterdam gives it early access to unpartnered assets that are still pre-venture-syndicate.